Abstract 15612: A Novel Pump Device for Delivery of Intravenous Thrombolytics in Resource Limited Settings
INTRODUCTION: Thrombolytics are the mainstay of therapy for ST-elevation MI (STEMI) and ischemic stroke in low-and-middle-income countries (LMICs) without access to angiography. Streptokinase and alteplase (tPA) are delivered as small volumes over 60 minutes for the treatment of STEMI and stroke, respectively. Widespread thrombolytic utilization for STEMI and stroke in LMICs is limited by pump cost, availability, consumables, and power consumption.
Hypothesis: We assessed the accuracy, power consumption, and mechanical integrity of AutoSyP -- a novel pump using standard 60 mL syringes to deliver tPA over 60 minutes.
METHODS: A clinician-engineering design team was tasked with developing a low-cost, low-power device for intravenous drug delivery. Standard design process was followed to produce a prototype.
RESULTS: AutoSyP uses a double-pawl ratchet mechanism controlled by a stepper motor to intermittently release a constant-force spring and compress a syringe (Fig. 1). A microcontroller customized for tPA drives the stepper motor.
The potential energy of the spring powers syringe compression, consuming 2W versus 20W for standard pumps. Twenty patients on 60-minute tPA protocols may be treated on one battery charge.
Four 60-minute mock tPA infusions with a target of 60 mL delivered a mean of 59.6 mL (SEM 0.1 mL) for 99.8% accuracy (Fig. 2).
In mechanical integrity simulations, AutoSyP withstood a 3ft drop test without deformation or fracture. The prototype costs $520 with target production of $300.
Conclusions: AutoSyP is a novel low-cost pump that accurately delivers small volumes over 60 minutes with ultra-low power consumption.
- © 2013 by American Heart Association, Inc.